18 results
Thrombotic Microangiopathy - TTP VS HUS

Big picture points : Often hard to differentiate the two entities,
Often hard to differentiate ... HUGE treatment ... thrombocytopenia #Comparison ... #Diagnosis #Table ... #Hematology
Stroke and bleeding risk stratification with the CHADS2-VASc and HAS-BLED schemas

#Diagnosis #Hematology #CHADS2 #CHADS2VASc #HASBLED #Comparison
Stroke and bleeding ... risk stratification ... CHADS2-VASc and HAS-BLED ... #Diagnosis #Hematology ... CHADS2VASc #HASBLED #Comparison
Bleeding risk calculators - HAS-BLED (atrial fibrillation) and IMPROVE (VTE prophylaxis for inpatients)
Important notes:
 • No
Bleeding risk calculators ... - HAS-BLED (atrial ... risk tools have ... validated for VTE treatment ... Anticoagulation #Factors #Hematology
Comparison of anti-diabetic or anti-hyperglycemic agents

There are numerous anti-hyperglycemic agents available to manage Type 2 diabetes.
Comparison of anti-diabetic ... has its own benefits ... and risks, and ... pharmacotherapy #table ... endocrinology #treatment
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
For most indications ... lead to severe bleeding ... #pharmacology #treatment ... #medications #table ... decisionaid #cardiology #hematology
CHA2DS2VASc vs HAS-BLED scores for stroke risk and bleed risk on anticoagulation

C	Congestive Heart Failure	1

H	Hypertension	1

A2	Age >75	2

D	Diabetes Mellitus	1

S2	Stroke,
CHA2DS2VASc vs HAS-BLED ... and bleed risk ... S Stroke 1 B Bleeding ... CHADS2VASc #HASBLED #Comparison ... AFib #Diagnosis #Hematology
Causes of Thrombocytopenia and Platelet Disorders - Differential Diagnosis and Workup
History:
 - Prior platelet count, family
Platelet Disorders - Differential ... family history - Medications ... - History of bleeding ... l MD SOAP) - Risks ... Causes #Workup #hematology
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
: 33% • Treatment ... : No • Treatment ... Transfusion #Reactions #hematology ... #diagnosis #comparison ... #table
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
interactions) Cancer-treatment ... DOACs thereby leading ... whereas edoxaban has ... Chemotherapy #Oncology #Hematology ... #Interactions #Table
Opioid Use Disorder Medications - Pharmacokinetics

Buprenorphine is a partial mu-opioid receptor agonist with low intrinsic activity,
dissociation rate, leading ... the sublingual tablet ... increases the risk ... Pharmacokinetics #Comparison ... #Table #Pharmacology